These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 15109676

  • 1. Design, synthesis and evaluation of potential inhibitors of HIV gp120-CD4 interactions.
    Boussard C, Klimkait T, Mahmood N, Pritchard M, Gilbert IH.
    Bioorg Med Chem Lett; 2004 May 17; 14(10):2673-6. PubMed ID: 15109676
    [Abstract] [Full Text] [Related]

  • 2. CD4 mimics targeting the mechanism of HIV entry.
    Yamada Y, Ochiai C, Yoshimura K, Tanaka T, Ohashi N, Narumi T, Nomura W, Harada S, Matsushita S, Tamamura H.
    Bioorg Med Chem Lett; 2010 Jan 01; 20(1):354-8. PubMed ID: 19926478
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of HIV-1 envelope-mediated fusion by synthetic batzelladine analogues.
    Bewley CA, Ray S, Cohen F, Collins SK, Overman LE.
    J Nat Prod; 2004 Aug 01; 67(8):1319-24. PubMed ID: 15332849
    [Abstract] [Full Text] [Related]

  • 4. A peptidomimetic HIV-entry inhibitor directed against the CD4 binding site of the viral glycoprotein gp120.
    Neffe AT, Meyer B.
    Angew Chem Int Ed Engl; 2004 May 24; 43(22):2937-40. PubMed ID: 15170309
    [No Abstract] [Full Text] [Related]

  • 5. CD4 mimics targeting the HIV entry mechanism and their hybrid molecules with a CXCR4 antagonist.
    Narumi T, Ochiai C, Yoshimura K, Harada S, Tanaka T, Nomura W, Arai H, Ozaki T, Ohashi N, Matsushita S, Tamamura H.
    Bioorg Med Chem Lett; 2010 Oct 01; 20(19):5853-8. PubMed ID: 20728351
    [Abstract] [Full Text] [Related]

  • 6. Discovery of a small molecule inhibitor through interference with the gp120-CD4 interaction.
    Williams DH, Adam F, Fenwick DR, Fok-Seang J, Gardner I, Hay D, Jaiessh R, Middleton DS, Mowbray CE, Parkinson T, Perros M, Pickford C, Platts M, Randall A, Siddle D, Stephenson PT, Tran TD, Vuong H.
    Bioorg Med Chem Lett; 2009 Sep 01; 19(17):5246-9. PubMed ID: 19620004
    [Abstract] [Full Text] [Related]

  • 7. A dynamic target-based pharmacophoric model mapping the CD4 binding site on HIV-1 gp120 to identify new inhibitors of gp120-CD4 protein-protein interactions.
    Caporuscio F, Tafi A, González E, Manetti F, Esté JA, Botta M.
    Bioorg Med Chem Lett; 2009 Nov 01; 19(21):6087-91. PubMed ID: 19783140
    [Abstract] [Full Text] [Related]

  • 8. Small molecular CD4 mimics as HIV entry inhibitors.
    Narumi T, Arai H, Yoshimura K, Harada S, Nomura W, Matsushita S, Tamamura H.
    Bioorg Med Chem; 2011 Nov 15; 19(22):6735-42. PubMed ID: 22014753
    [Abstract] [Full Text] [Related]

  • 9. Synthetic bivalent CD4-mimetic miniproteins show enhanced anti-HIV activity over the monovalent miniprotein.
    Li H, Song H, Heredia A, Le N, Redfield R, Lewis GK, Wang LX.
    Bioconjug Chem; 2004 Nov 15; 15(4):783-9. PubMed ID: 15264865
    [Abstract] [Full Text] [Related]

  • 10. Scorpion-toxin mimics of CD4 in complex with human immunodeficiency virus gp120 crystal structures, molecular mimicry, and neutralization breadth.
    Huang CC, Stricher F, Martin L, Decker JM, Majeed S, Barthe P, Hendrickson WA, Robinson J, Roumestand C, Sodroski J, Wyatt R, Shaw GM, Vita C, Kwong PD.
    Structure; 2005 May 15; 13(5):755-68. PubMed ID: 15893666
    [Abstract] [Full Text] [Related]

  • 11. Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4.
    Zhao Q, Ma L, Jiang S, Lu H, Liu S, He Y, Strick N, Neamati N, Debnath AK.
    Virology; 2005 Sep 01; 339(2):213-25. PubMed ID: 15996703
    [Abstract] [Full Text] [Related]

  • 12. Design and optimisation of potent gp120-CD4 inhibitors.
    Tran TD, Adam FM, Calo F, Fenwick DR, Fok-Seang J, Gardner I, Hay DA, Perros M, Rawal J, Middleton DS, Parkinson T, Pickford C, Platts M, Randall A, Stephenson PT, Vuong H, Williams DH.
    Bioorg Med Chem Lett; 2009 Sep 01; 19(17):5250-5. PubMed ID: 19632839
    [Abstract] [Full Text] [Related]

  • 13. Extension of the polyanionic cosalane pharmacophore as a strategy for increasing anti-HIV potency.
    Cushman M, Insaf S, Paul G, Ruell JA, De Clercq E, Schols D, Pannecouque C, Witvrouw M, Schaeffer CA, Turpin JA, Williamson K, Rice WG.
    J Med Chem; 1999 May 20; 42(10):1767-77. PubMed ID: 10346929
    [Abstract] [Full Text] [Related]

  • 14. How can (-)-epigallocatechin gallate from green tea prevent HIV-1 infection? Mechanistic insights from computational modeling and the implication for rational design of anti-HIV-1 entry inhibitors.
    Hamza A, Zhan CG.
    J Phys Chem B; 2006 Feb 16; 110(6):2910-7. PubMed ID: 16471901
    [Abstract] [Full Text] [Related]

  • 15. Functional design of potential inhibitors of human immunodeficiency virus (HIV) binding to CD4+ target cells: a molecular model of gp120 predicts ligand binding.
    Gabriel JL, Mitchell WM.
    Drug Des Discov; 1996 Oct 16; 14(2):103-14. PubMed ID: 9010617
    [Abstract] [Full Text] [Related]

  • 16. Design, Synthesis, and Antiviral activity of 1,2,3,4-Tetrahydropyrimidine derivatives acting as novel entry inhibitors to target at "Phe43 cavity" of HIV-1 gp120.
    Senapathi J, Bommakanti A, Kusuma V, Vangara S, Kondapi AK.
    Bioorg Med Chem; 2021 Dec 15; 52():116526. PubMed ID: 34839157
    [Abstract] [Full Text] [Related]

  • 17. Rational conversion of noncontinuous active region in proteins into a small orally bioavailable macrocyclic drug-like molecule: the HIV-1 CD4:gp120 paradigm.
    Hurevich M, Swed A, Joubran S, Cohen S, Freeman NS, Britan-Rosich E, Briant-Longuet L, Bardy M, Devaux C, Kotler M, Hoffman A, Gilon C.
    Bioorg Med Chem; 2010 Aug 01; 18(15):5754-61. PubMed ID: 20619663
    [Abstract] [Full Text] [Related]

  • 18. Small-molecule HIV-1 gp120 inhibitors to prevent HIV-1 entry: an emerging opportunity for drug development.
    Kadow J, Wang HG, Lin PF.
    Curr Opin Investig Drugs; 2006 Aug 01; 7(8):721-6. PubMed ID: 16955683
    [Abstract] [Full Text] [Related]

  • 19. Molecular dynamics study of the proposed beta-hairpin form of the switch domain from HIV1 gp120 alone and complexed with an inhibitor of CD4 binding.
    Graf von Stosch A, von der Lieth CW, Reed J.
    Proteins; 1999 Feb 01; 34(2):197-205. PubMed ID: 10022355
    [Abstract] [Full Text] [Related]

  • 20. Atomic insight into the CD4 binding-induced conformational changes in HIV-1 gp120.
    Hsu ST, Bonvin AM.
    Proteins; 2004 May 15; 55(3):582-93. PubMed ID: 15103622
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.